Outlook Therapeutics Inc
41O
Company Profile
Business description
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Contact
111 S. Wood Avenue
Suite 100
IselinNJ08852
USAT: +1 609 619-3990
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2026
Employees
23
Stocks News & Analysis
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,264.30 | 8.50 | 0.09% |
CAC 40 | 7,918.00 | 123.36 | -1.53% |
DAX 40 | 24,241.46 | 369.79 | -1.50% |
Dow JONES (US) | 45,479.60 | 878.82 | -1.90% |
FTSE 100 | 9,427.47 | 81.93 | -0.86% |
HKSE | 26,290.32 | 462.27 | -1.73% |
NASDAQ | 22,204.43 | 820.20 | -3.56% |
Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
NZX 50 Index | 13,467.26 | 103.60 | -0.76% |
S&P 500 | 6,552.51 | 182.60 | -2.71% |
S&P/ASX 200 | 8,958.30 | 9.20 | 0.10% |
SSE Composite Index | 3,897.03 | 36.94 | -0.94% |